V 270

Drug Profile

V 270

Alternative Names: HBsAg-1018; HBV vaccine preventative - Dynavax; HBV-ISS preventative vaccine; Hepatitis B vaccine 1018-ISS conjugate - Dynavax; Hepatitis B vaccine preventative - Dynavax; HEPLISAV; HEPLISAV-B; V270

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hepatitis B

Most Recent Events

  • 14 Nov 2016 V 270 is available for licensing as of 14 Nov 2016. www.dynavax.com
  • 14 Nov 2016 Dynavax Technologies receives complete response letter from the FDA for V 270 in Hepatitis B
  • 26 Oct 2016 Sub-group efficacy data from a phase III trial in Hepatitis B presented at the Infectious Diseases Society of America's annual IDWeek meeting (IDSA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top